Atara Biotherapeutics Stock Investor Sentiment
| ATRA Stock | USD 6.74 0.37 5.20% |
About 55% of Atara Biotherapeutics' investor base is interested to short. The analysis of the overall investor sentiment regarding Atara Biotherapeutics suggests that many traders are impartial. The current market sentiment, together with Atara Biotherapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Atara Biotherapeutics stock news signals to limit their universe of possible portfolio assets.
Atara |
Atara Biotherapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Atara Biotherapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Far too much social signal, news, headlines, and media speculation about Atara Biotherapeutics that are available to investors today. That information is available publicly through Atara media outlets and privately through word of mouth or via Atara internal channels. However, regardless of the origin, that massive amount of Atara data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Atara Biotherapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Atara Biotherapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Atara Biotherapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Atara Biotherapeutics alpha.
Atara Biotherapeutics Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | ATRA Stock Down After FDA Issues CRL for Rare Blood Cancer Candidate | 01/17/2025 |
2 | Acquisition by Eric Hyllengren of 34050 shares of Atara Biotherapeutics subject to Rule 16b-3 | 01/27/2025 |
3 | Wolf Haldenstein Adler Freeman Herz LLP announces that it is investigating Atara Biotherapeutics, Inc. for potential violations of securities laws | 02/03/2025 |
4 | Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635 | 02/07/2025 |
5 | LB Pharmaceuticals Announces Key Executive Appointments to Support Growth and Late-Stage Development of LB-102 | 02/11/2025 |
6 | Geron Reports Q4 Loss, Tops Revenue Estimates | 02/26/2025 |
7 | Praxis Precision Medicines, Inc. Reports Q4 Loss, Tops Revenue Estimates | 02/28/2025 |
8 | Disposition of 1059 shares by Jill Henrich of Atara Biotherapeutics at 6.997 subject to Rule 16b-3 | 03/05/2025 |
9 | Atara Biotherapeutics Releases Earnings Results, Beats Estimates By 2.63 EPS | 03/07/2025 |
10 | Acquisition by Fust Matthew K of 79500 shares of Atara Biotherapeutics at 1.53 subject to Rule 16b-3 | 03/13/2025 |
Complementary Tools for Atara Stock analysis
When running Atara Biotherapeutics' price analysis, check to measure Atara Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atara Biotherapeutics is operating at the current time. Most of Atara Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Atara Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Atara Biotherapeutics' price. Additionally, you may evaluate how the addition of Atara Biotherapeutics to your portfolios can decrease your overall portfolio volatility.
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |